Fenben is a drug commonly used as a veterinary medicine. It is safe to use on animals, but it has not been extensively tested for humans for long-term exposure. Despite the lack of scientific evidence, many people are taking the drug on their own, believing that it can prevent cancer from recurring or even cure it. However, it is important to note that if you are considering using this drug as part of your treatment protocol, please consult a healthcare professional first.
The post claims fenbendazole kills cancer cells “unlike your other NHS shit that just make them lay dormant/sleep untill [sic] they are ready to wake back up.” The claim is misleading because there is no evidence that fenbendazole can do what it claims to do. There is also no evidence that it can prevent recurrent cancer, either, and it may not be a suitable drug for everyone who has cancer.
A number of studies in cell culture and mice suggest that fenbendazole can be effective against cancer, but none of them show that it is actually effective in human patients. This is because it is impossible to know if a treatment will be effective or safe in a patient until it is properly tested in a clinical trial.
In cell culture, fenbendazole caused death in cancer cells by interfering with microtubule dynamics. It also induced p53 activation and inhibited glycolytic enzymes, including hexokinase II. In addition, fenbendazole prevented the growth of human xenografts in nude mice by causing tumor-specific apoptosis.
Another study in vivo showed that fenbendazole significantly reduced tumor volume and inhibited the sensitivity of EMT6 xenografts to radiation. In this experiment, fenbendazole was given to athymic nu/nu mice with established A549 xenografts, and the drug was administered every second day for 12 days. Tumor size and weight were measured, and vascularity was quantified by spectrophotometrically measuring hemoglobin content. In fenbendazole-treated mice, tumors were smaller and less vascular.
A third study in vivo found that fenbendazole significantly decreased the growth of human lung cancer xenografts in athymic nu/nu mice, and the drug reduced vascularity by causing apoptosis. In a fourth study, athymic nu/nu mice were xenografted with A549 cells and treated orally with fenbendazole every second day for 12 days. Tumors were excised, weighed and measured, and there was a significant reduction in tumor volume and weight. In addition, fenbendazole inhibited the growth of A549 xenografts in these mice by inducing apoptosis and inhibiting glucose uptake. Benzimidazole compounds interfere with energy metabolism in malignant cells by blocking ATP production and uptake, and this mechanism may be responsible for their anticancer activity. The anticancer effect of fenbendazole is further enhanced by the coadministration of other agents that target mitochondrial and metabolic pathways involved in carcinogenesis. This makes it a promising candidate for the development of future therapeutics against malignant diseases. fenben for humans